October 12, 2020
Takashi Masamura, Franchise Head, Immunology Franchise, Sanofi Japan Sanofi’s anti-IL-4/IL-13 antibody Dupixent (dupilumab) is racking up strong growth in Japan despite a 20%-plus price cut this April, pulling in annual sales of 22 billion yen on an NHI price basis...read more